Drug Database
Back to search

Italy· 022803047

ANTEPSIN*orale sosp 200 ml 1 g/5 ml

A sucralfate product containing sucralfato, registered in Italy by LABORATORI BALDACCI SpA, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in Italy (AIFA class A)ATC A02BX02

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · ITPublic registernormalisedANTEPSIN*orale sosp 200 ml 1 g/5 mlATCA02BX02REGISTER NO.022803047PACKS LISTED1CHECKEDJune 4, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about sucralfatoAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Sucralfate is registered in 13 of 19 countries.

Countries holding a registration under ATC A02BX02 (sucralfate), each read from that country’s own register.

  • This record: Italy
  • 7 of them publish a price we can compare per daily dose
Search sucralfate products by name

Sucralfate · ATC A02BX02

13 / 19 countries

  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of sucralfate costs, country by country.

Normalised to the WHO defined daily dose (4 g), so markets compare like for like.

  • Italy: $0.62 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Sucralfate · price per daily dose (4 g)

USD · FX 28 Sept 2026

  • IT Italy$0.62
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Active substance
Sucralfato
Manufacturer
LABORATORI BALDACCI SpA
Country
Italy (IT)
ATC code
A02BX02
ATC class
Sucralfate
Defined daily dose
4 g, O
Reimbursed
Yes
Last checked
June 4, 2026

Packs & prices · 1

1 priced
  • aic
    022803047
    ANTEPSIN*orale sosp 200 ml 1 g/5 ml
    EUR 8.49

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

504 interactions on record for sucralfate.

Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check sucralfate against other medicinesHow interaction checks work

Sucralfate · interactions on record

504 records

  • 5 severe
  • 116 moderate
  • 46 minor
  • 337 info

Most severe, free to view

  • ParicalcitolA11CC07severe
  • ParicalcitolH05BX02severe
  • DoxercalciferolH05BX03severe
  • DolutegravirJ05AJ03severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Sucralfate in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All sucralfate products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Austria · Sucralan, Sucralfat Genericon
  • Germany · Sucrabest
  • Denmark · Antepsin, Peptonorm
  • Finland · Antepsin, Peptonorm
  • France · Keal, Ulcar
  • United Kingdom (Northern Ireland) · Sucralfate Roma Pharmaceuticals
  • Greece · Peptonorm
  • Hungary · Peptonorm
  • Iceland · Antepsin
  • Netherlands · Sucralfaat Sandoz, Sucralfaat Teva
  • Norway · Antepsin
  • Portugal · Sucralfato Generis, Sucralfato Jaba
  • Sweden · Andapsin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/23c95f70-5d7e-4b6e-b8be-a663e716d76c
GET /v1/drugs/23c95f70-5d7e-4b6e-b8be-a663e716d76c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "price": 8.49,
  "source": "aifa",
  "currency": "EUR",
  "strength": "SUCRALFATO 20% 200ML USO ORALE",
  "substance": "Sucralfato",
  "equivalence_group": "AHD",
  "transparency_flag": null
}
API referenceMCP serverPlans

See everything about sucralfate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console